Regentis Biomaterials Jumps After Firm Scraps Public Offer
RGNT soared up to 850% after Regentis withdrew its planned U.S. share offering, removing immediate dilution risk but leaving funding concerns unresolved as the company faces a $13.6 million annual loss, $7.4 million in cash, and a “going concern” warning; investors now await Q3 European GelrinC surgeon training as the next catalyst.